Shopping Cart
Remove All
Your shopping cart is currently empty
Atacicept
😃Good
Catalog No. T78302Cas No. 845264-92-8
Alias VT-001, VT001
Atacicept (TACI-Ig) is a homodimeric fusion protein that inhibits B-cell stimulation by binding to B-lymphocyte stimulatory factors and proliferation-inducing ligands, and can be used in the study of systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis, multiple sclerosis, and various B-cell malignancies.
Atacicept
Atacicept
😃Good
Catalog No. T78302Alias VT-001, VT001Cas No. 845264-92-8
Atacicept (TACI-Ig) is a homodimeric fusion protein that inhibits B-cell stimulation by binding to B-lymphocyte stimulatory factors and proliferation-inducing ligands, and can be used in the study of systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis, multiple sclerosis, and various B-cell malignancies.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $448 | - | In Stock | |
| 5 mg | $1,170 | - | In Stock | |
| 10 mg | $1,870 | - | In Stock |
Add to Cart
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Batch Information
Select Batch
Purity:97.9% (SDS-PAGE); 98.7% (SEC-HPLC)
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Storage & Solubility Information
| Description | Atacicept (TACI-Ig) is a homodimeric fusion protein that inhibits B-cell stimulation by binding to B-lymphocyte stimulatory factors and proliferation-inducing ligands, and can be used in the study of systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis, multiple sclerosis, and various B-cell malignancies. |
| In vivo | Atacicept (100 μg; intraperitoneal injection; three times per week for 14 days) significantly reduced the number of mature B cells and serum antibody levels in BALB/c mice. Atacicept (100 μg; intraperitoneal injection; three times per week for 21 days) effectively inhibited disease progression and autoantibody titers in a mouse model of collagen-induced arthritis (CIA).[1] |
| Synonyms | VT-001, VT001 |
| Reactivity | Human |
| Application | Functional assay |
| Antibody Type | Monoclonal |
| Endotoxin | <0.9 EU/mg |
| Conjucates | Unconjugated |
| Target | APRIL/BAFF |
| Molecular Weight | 35.36 kDa |
| Cas No. | 845264-92-8 |
| Storage | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Keywords
Preview
Related Tags: buy Atacicept | purchase Atacicept | Atacicept cost | order Atacicept | Atacicept in vivo | Atacicept molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.